Interestingly, the observation that some "morbid predisposition" is at the heart of the problem in some families was actually made before Mendel's laws were known (1) . Indeed, a precise genotypephenotype prediction of several rare syndromes that are now well-known clinical entities-such as HoltOram or Char syndromes-predates the arrival of modern genetic technologies. Over the years, such cases, in particular those with a familial basis, were instrumental for 2 reasons: 1) for epidemiological investigations, they offered a means to estimate the burden of disease attributable to genetic factors; and 2) with the advent of more sophisticated genetic tools, they provided a gateway to dissect the molecular basis of congenital heart disease (CHD).
Over the last decade, tremendous progress was made in the area of genetic technologies. This includes genotyping, calling of copy number variants, and next-generation sequencing (NGS) of the entire coding part of the genome, called whole-exome sequencing (WES). As a consequence, we better understand the genetic basis of numerous forms of syndromic and nonsyndromic CHD (2), although the proportion of cases explained by these studies remains fairly small. For example, copy number variants are thought to explain 5% to 20% of selected CHD, and WES studies implicate de novo mutations in 10% of sporadic severe cases (3) (4) (5) . Montréal, Quebec, Canada. Dr. Andelfinger has reported that he has no relationships relevant to the contents of this paper to disclose. andelfinger@recherche-ste-justine.qc.ca. 
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